<DOC>
	<DOCNO>NCT00955617</DOCNO>
	<brief_summary>This study intra-individual comparison DOTAREM®-enhanced MRA GADOVIST®-enhanced MRA diagnosis clinically significant abdominal low limb arterial disease .</brief_summary>
	<brief_title>DOTAREM®-Enhanced MRA Compared GADOVIST®-Enhanced MRA Patients With Abdominal Lower Limb Arterial Diseases</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Female male , age ≥ 18 year Patient suffer Peripheral Arterial Occlusive Disease ( PAOD ) stage II III . Patients severely impaired renal function eGFR ( MDRD ) &lt; 50ml/min ( eGFR base recent serum creatinine MDRD formula young 21 day ) . Patient plan undergo therapeutic intervention vessel interest two MRA procedure . Patient major cardiovascular event within 30 day prior inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Dotarem</keyword>
	<keyword>Gadovist</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>MRA</keyword>
</DOC>